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APOA5 encodes a novel apolipoprotein (apo A-V)
which appears to be a modulator of plasma triglyceride
(TG). In apoA5 knock out mice plasma TG level
increases almost fourfold, whereas in human APOA5
transgenic mice it decreases by 70%. Some SNPs in
the APOA5 gene have been associated with variations
in plasma TG in humans. In addition, hypertriglyceri-
daemic (HTG) patients have been identified who car-
ried rare nonsense mutations in the APOA5 gene
(Q139X and Q148X), predicted to result in apo A-V
deficiency. In this study we report a 17-year-old male
with high TG and low high density lipoprotein choles-
terol (HDL-C), who at the age of two had been found
to have severe HTG and eruptive xanthomas suggest-
ing a chylomicronaemia syndrome. Plasma postheparin
LPL activity, however, was normal and no mutations
were found in LPL and APOC2 genes. The sequence of
APOA5 gene revealed that the patient was homozygous
for a point mutation (c.289 C>T) in exon 4, converting
glutamine codon at position 97 into a termination
codon (Q97X). Apo A-V was not detected in patient’s
plasma, indicating that he had complete apo A-V defi-
ciency. The administration of a low-fat and low-oligo-
saccharide diet, either alone or supplemented with x-3
fatty acids, started early in life, reduced plasma TG to a
great extent but had a negligible effect on plasma
HDL-C. Loss of function mutations of APOA5 gene
may be the cause of severe HTG in patients without
mutations in LPL and APOC2 genes.
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Introduction
Hypertriglyceridaemia (HTG) usually refers to fasting
plasma triglyceride (TG) level above the 95th percen-
tile for age and sex; it can be divided into primary
and secondary type. Primary HTG is assumed to have
a strong genetic basis; however, the molecular defect
underlying primary HTG is known in <10% of cases
[1].
Hyperlipidaemia type I and hyperlipidaemia type V
are lipoprotein disorders characterized by the patho-
logical presence of chylomicrons in the fasting state.
Their clinical features include eruptive xanthomas,
lipaemia retinalis, hepato-splenomegaly, recurrent
abdominal pain and increased risk of pancreatitis [2].
The accumulation of chylomicrons (type I) or chylo-
microns and VLDL (Type V) is caused by defects in
the lipolytic cascade due to loss of function mutations
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in the genes encoding lipoprotein lipase (LPL) or its
activator apo C-II (APOC2) [2].
Familial HTG (hyperlipoproteinaemia type IV) is
characterized by an isolated elevation of VLDL. This
disorder has a population prevalence of 5–10% but its
molecular basis is still unknown; it is likely to be
polygenic and strongly affected by environmental
factors and metabolic stress [1].
In familial combined hyperlipidaemia (FCHL) the ele-
vation of plasma TG is due to increased level of
VLDL, which is associated with increased level of
LDL and hepatic overproduction of apolipoprotein B
[3]. The molecular basis underlying FCHL is largely
unknown; genetic variants in APOA1 ⁄C3 ⁄A4 ⁄A5 clus-
ter and in the recently identified USF1 gene appear to
contribute to the phenotype [4, 5].
The increased TG levels found in dysbetalipoproteina-
emia (hyperlipoproteinaemia type III) is due to the
accumulation of TG-rich lipoprotein remnants (e.g. b-
VLDL). Patients with this disorder are typically
homozygous for the rare apo E-2 isoform, which
shows a defective binding to LDL-receptor when
compared with the most common apo E-3 isoform.
The phenotypic expression of dysbetalipoproteina-
emia, however, requires some additional factors such
as obesity, type 2 diabetes or hypothyroidism [3].
The recently identified APOA5 gene, which encodes
apolipoprotein A-V (apo A-V), appears to be a key
modulator of plasma TG homeostasis in rodents as
well as in humans. When the human APOA5 gene
was expressed in transgenic mice, the plasma TG
level decreased by 70%, whereas when mouse apoa5
gene was inactivated, the plasma TG increased four-
fold, compared with control mice [6]. These results
suggested an inverse correlation between apo A-V
concentration and plasma TG level in mice. Single
nucleotide polymorphisms in the APOA5 gene (e.g.
1131T ⁄C in the 5¢-flanking region and c.56 C ⁄G in
the coding region) have been associated with differ-
ences in plasma TG levels in humans [6–10]. Carriers
of the rare alleles )1131C or c.56 G have higher
plasma TG than carriers of the corresponding common
alleles [7–10]. Interestingly, human studies do not
support the inverse correlation between plasma apo
A-V and TG concentration that has emerged from
studies in mice. In fact, plasma apo A-V level was
found to be positively correlated with TG level in
subjects from the general population, as well as in
patients with HTG and in patients with type 2 dia-
betes [11–16].
Rare loss of function mutations in APOA5 gene have
been reported in humans [17]. In 2005 we identified a
9-year-old boy with severe HTG, who was homozy-
gous for a nonsense mutation predicted to result in
truncated apo A-V (Q148X) [18]. He was regarded to
have complete apo A-V deficiency as no apo A-V
was detected in his plasma [17]. Another patient with
type V hyperlipidaemia and recurrent episodes of pan-
creatitis was found to be homozygous for a different
apo A-V mutation (Q139X) predicted to cause com-
plete apo A-V deficiency [19]. So it looks as though
apo A-V deficiency in humans recapitulates, to some
extent, the plasma lipid abnormalities observed in
apoa5 knock-out mice, suggesting that the absence of
apo A-V causes a substantial disruption of the metab-
olism of TG-rich lipoproteins.
In the present study we report a 17-year-old patient
with primary HTG detected early in life, who was
found to be homozygous for a novel nonsense muta-
tion of APOA5 gene. No apo A-V was detectable in




Proband T.L. is a 17-year-old Caucasian male, who at
the age of two was found to have eruptive cutaneous
xanthomas and severe HTG in the fasting state, sug-
gesting hyperchylomicronaemia syndrome. He never
had abdominal pain, hepatosplenomegaly nor pancrea-
titis and developed normally. Routine laboratory tests,
with the exception of plasma lipids, were within the
reference range. The proband has been treated with
low-fat and low-oligosaccharide diet since infancy;
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the good compliance to this diet was associated with
a substantial reduction of plasma TG level (Table 1)
and a progressive disappearance of eruptive xanthom-
as. At the age of 12 he started treatment with x-3
fatty acids (3 g day)1) which, however, was discon-
tinued after 2 years because of poor compliance.
Medium Chain Triglycerides (MCT) supplementation
or fibrate therapy were never prescribed.
At age 16 the proband was referred to the Lipid
Clinic of the University Hospital with the clinical
diagnosis of primary severe HTG (type V). Alcohol
assumption was denied. He was a nonsmoker and
practised regular physical activity (basketball player).
On physical examination he was found healthy and
lean (BMI 19.5 kg m)2, waist circumference 71 cm).
He had normal blood pressure and heart rate; no skin,
tendons, thoracic, abdominal or vascular abnormalities
were observed. Tonsils, eyes and fundus oculi exam-
inations were normal. Abdominal ultrasound scan
confirmed the absence of visceral abnormalities. Rou-
tine laboratory tests for hepato-biliary, renal and
thyroid function were normal, as well as blood glu-
cose and blood cell count. ECG was normal.
On a low-fat diet, the level of total cholesterol (T-C),
TG and HDL cholesterol (HDL-C) were 4.08, 5.90
and 0.75 mmol L)1, respectively (Table 1). The addi-
tion of x-3 fatty acids (3 g day)1) lowered triglyce-
rides to 2.98 mmol L)1 but had little effect on plasma
HDL-C (Table 1).
Proband’s parents were apparently unrelated; they
were in good health and had no family history of dy-
slipidaemia or premature coronary heart disease. The
proband’s 7-year-old brother was also in good health.
Routine laboratory tests of these family members
were within the normal values (Table 2).
Plasma lipid analysis and LPL assay
T-C, HDL-C, TG, apo A-I and apo B levels were
determined by standard methods and plasma lipopro-
tein were separated by density gradient ultracentrifuga-
tion in a SW41 Beckman rotor at 170 000 · g at
15 C [20]. The measurement of plasma apo A-V and
apo C-III was performed by ELISA assay; immunoblot
analysis of plasma apo A-V was conducted as
described [11]. Lipoprotein and hepatic lipase activi-
ties in postheparin plasma were measured as previ-
ously reported [18].
Analysis of candidate genes
Genomic DNA was extracted from peripheral blood
leucocytes by a standard procedure. All exons and the
promoter region of LPL and APOC2 genes were
amplified by polymerase chain reaction from genomic
Table 1 Plasma lipids and lipoproteins in proband T.L.
Years
of age Treatment TG T-C HDL-C LDL-C Apo B Apo A-I
2 None 9.65 5.58 0.59 n.d. n.d. n.d.
3 Diet 2.82 4.73 0.58 n.d n.d n.d.
4 Diet 3.59 5.68 0.80 1.47 175 118
5 Diet 5.13 4.60 0.59 n.d. n.d. n.d.
10 Diet 3.61 3.18 0.67 1.49 123 173
11 Diet 5.08 4.34 0.88 n.d. n.d. n.d.
12 Diet + x-3 3.73 4.48 0.90 n.d. n.d. n.d.
13 Diet + x-3 2.37 3.18 0.64 n.d. n.d. n.d.
13 Diet 4.02 4.37 0.82 1.57 102 126
14 Diet 5.28 4.19 0.69 n.d. n.d. n.d.
15 Diet 12.03 4.96 0.59 n.d. n.d. n.d.
16 Diet 5.90 4.08 0.75 1.73 n.d. n.d.
17 Diet + x-3 2.98 3.93 0.75 1.68 80 112
Plasma level of TG, T-C, HDL-C and LDL-C are given in
mmol L)1; plasma level of apo B and apo A-I are given in
mg dL)1.
Diet + x-3 fatty acids 3 g day)1 (oral ethyl-ester of polyunsaturated
fatty acids EPA and DHA 85%, EPA ⁄DHA = 0.9–1.5).
n.d., not determined.
Table 2 Plasma lipids and lipoproteins in proband’s family
members
Subject TG T-C HDL-C LDL-C Apo B Apo A-I
Father 0.79 5.85 1.26 4.54 128 154
Mother 1.27 4.25 1.21 2.86 78 157
Brother 0.56 3.69 1.03 2.74 68 127
Plasma level of TG, T-C, HDL-C and LDL-C are given in
mmol L)1; plasma level of apo B and apo A-I are given in
mg dL)1.
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DNA and sequenced as described [18]. The APOA5
gene was amplified and sequenced as reported [18].
The mutation of APOA5 gene found in the proband,
which eliminates a PstI restriction site in exon 4, was
confirmed by restriction fragment analysis of PCR-
amplified 5¢ region of exon 4, using the following
primers: 5¢-CGG CCT GGA TAT CTG TCC CC-3¢
(forward primer) and 5¢-CCC AGT GCC TGC AAA
GGC TC-3¢ (reverse primer). The amplification condi-
tions were 96 C for 5 min, 96 C for 1 min per
61.1 C for 1 min per 72 C for 1 min for 35 cycles,
followed by 72 C for 5 min. The amplification prod-
uct (662 bp) was digested with PstI and the fragments
were separated by 2% agarose gel electrophoresis.
This procedure was used to screen the mutation in
100 randomly selected normolipidaemic subjects.
Nomenclature of the mutation was according to the
recommendations of the Human Genome Variation
Society (the numerical series of codons includes the
sequence of the signal peptide, http://www.hgvs.org/
mutnomen).
The proband and family members were also geno-
typed for the following polymorphisms: )482 C ⁄T in
APOC3 gene; 2, 3 and 4 in APOE gene [19]. The
polymorphisms of APOA5 gene were assessed by
direct sequencing.
Ethical aspects
Informed consent was obtained from the patient and
his family and the study protocol was approved by
the local ethical committee of the University Hospital
of Modena.
Results
Plasma lipid and lipoproteins
The plasma lipid levels of the proband, recorded since
2 years of age, are shown in Table 1. Plasma TG
level shows large fluctuations over time (especially in
early teens), mostly in relation to the compliance of
the patient to the low-fat and low-oligosaccharide diet
and treatment with x-3 fatty acids. Plasma HDL-C
levels showed minor changes and were less affected
by dietary treatment. Plasma lipoprotein profile per-
formed when the patient’s TG level was
5.90 mmol L)1 showed a marked increase of the peak
corresponding to lipoproteins of density
<1.030 g mL)1 (Chylomicrons, VLDL + IDL) and a
reduction of LDL and HDL peaks (data not shown).
Plasma postheparin LPL activity (9.5 lmol F-
FA mL)1) was within the control range (8–
15 lmol FFA mL)1). The APOE genotype of the pro-
band was 34. The parents and the brother of the
proband were found to have normal lipid levels
(Table 2).
Sequence of APOA5 gene
Since the sequence analysis of LPL and APOC2 genes
in the proband revealed no abnormalitites, we
sequenced his APOA5 gene. This analysis revealed
that the proband was homozygous for a single nucleo-
tide substitution in exon 4 (c.289 C>T), which con-
verts the glutamine codon at position 97 into a
termination codon (Q97X) (Fig. 1). The presence of
this mutation was confirmed by restriction fragment
analysis after digestion of exon 4 with the restriction
enzyme Pst1, one site of which is abolished by the
mutation (Fig. 2).
The parents and the brother of the proband were
found to be heterozygous for the mutation (Figs 1
and 2). APOA5 gene polymorphisms in the proband’s
family are shown in Table 3. No carrier of the muta-
tion was found amongst 100 randomly selected nor-
molipidaemic individuals, nor in 30 patients with
primary severe HTG negative for mutations in LPL or
APOC2 genes. The proband was homozygous for the
common allele in the promoter of APOC3 gene ()482
C ⁄C), whilst his parents were heterozygous ()482
C ⁄T).
Plasma apo A-V and apo C-III levels
Apo A-V was undetectable in proband’s plasma; the
level of apo A-V in proband’s father (26.9 lg dL)1)
was within the control range (25.8 ± 14.6 lg dL)1).
Immunoblot analysis of proband’s plasma failed to
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reveal the presence of either wild type or truncated
apo A-V (Fig. 3). Plasma apo C-III level in the pro-
band was 18.4 mg dL)1 and 10.8 mg dL)1 in his
father (in fasting normolipidaemic subjects 10.6 ±
3.6 mg dL)1).
Discussion
In this study we report a novel mutation in APOA5
gene which causes a complete apo A-V deficiency.
This mutation was discovered during a survey of 48
patients with severe primary HTG, suspected to have
genetic defects in the lipolytic cascade. Amongst the
HTG patients found to be negative for mutations in
the LPL and APOC2 genes (30 subjects) we identified
three patients who carried pathogenic mutations of
APOA5 gene. The clinical and biochemical features
of the first two patients were described previously
[18, 21]. The patient investigated in the present study
was found to have eruptive xanthomas and milky
plasma in the fasting state at the age of 2 years, sug-
gestive of primary hyperchylomicronaemia syndrome.
He was put on a restricted dietary regimen (low-fat
and low-oligosaccharide diet) which was effective in
reducing plasma TG and eliminating eruptive xan-
thomas. Additional benefits were obtained with sup-
plementation of x-3 fatty acids. During the 15 years
of follow-up plasma TG exceeded the critical level of
10 mmol L)1 (regarded to be the threshold for the
risk of pancreatitis) only on one occasion. It is most
likely that the strict dietary regimen, the regular phys-
ical activity during adolescence and the maintenance
of an ideal BMI have contributed to prevent excessive
elevations of plasma TG over the years. The normal
postheparin LPL activity (performed at the age of 12)
cast doubt on the presence of defects in the lipolytic
cascade and the patient was referred to the laboratory
for molecular diagnosis at the age of 17. After the
exclusion of LPL and APOC2 genes, the analysis of
APOA5 gene showed that proband was homozygous
for a point mutation in APOA5 gene, predicted to
result in a short truncated protein (Q97X). Neither
wild type nor truncated apo A-V was detected in pro-
band’s plasma, thus confirming that the patient had a
complete apo A-V deficiency. The truncated protein
Q97X, if synthesized at all, is expected to be com-
pletely devoid of function, as it lacks some domains
involved in lipid binding (residues 192–238 and 301–
343), LPL activation (residues 192–238) and heparin
binding (residues 186–227) [22–24].
Phenotypically proband T.L. resembles the patient
with complete apo A-V deficiency who was homozy-
gous for the truncated apo A-V Q148X we reported
previously [18]. Both these young patients had severe
HTG since infancy, which was transmitted as a reces-
sive trait in the family. In both patients the adminis-
tration of a low-fat diet, especially if supplemented
with x-3 fatty acids, induced a substantial reduction
of plasma TG level (Table 4).
Although the mechanism by which apo A-V affects
plasma TG level is not fully understood, several
hypotheses have been proposed including: (i) an intra-
cellular effect on hepatic VLDL assembly and secre-




Fig. 1 Partial nucleotide sequence of exon 4 of APOA5
gene in a control subject, in proband T.L. and in his father.
The proband is homozygous for a C>T transition (c.289
C>T) converting the glutamine codon at position 97 into a
termination codon (Q97X). Proband’s father was heterozy-
gous for the same mutation.
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secretion of VLDL) and (ii) an effect on plasma
removal of TG-rich lipoprotein, either by a direct
modulation of the activity of lipoprotein lipase or by
an effect on the uptake of these lipoproteins (or their
remnants) by hepatocytes [24].
Some studies indicate that apo A-V facilitates the
action of LPL. In view of its high affinity for hepa-
rin, apo A-V would increase the binding of TG-rich
lipoproteins to glycosaminoglycans present on the
surface of endothelial cells, thus rendering these lipo-
proteins more accessible to LPL [25]. Recently, Nils-
son et al. [26] provided evidence that apo A-V binds
to two endocytotic receptors of the LDLR family,
LRP and SorLA, and mediates the binding of chylo-
microns to these receptors. They also put forward
the hypothesis that the main action of apo A-V is
exerted at the sinusoidal surface of the hepatocytes
rather than in the plasma compartment. Apo A-V
(which is synthesized exclusively in the liver)
Table 3 APOA5 gene polymor-










Proband T ⁄T A ⁄A C ⁄C G ⁄G T ⁄T
Father T ⁄T A ⁄A C ⁄C G ⁄G T ⁄T
Mother T ⁄T A ⁄A C ⁄C G ⁄G T ⁄T
Brother T ⁄T A ⁄A C ⁄C G ⁄G T ⁄T
(a)
(b)
Fig. 2 Restriction fragment analysis of exon 4 of APOA5 gene. Exon 4 was amplified by PCR and digested with the restric-
tion enzyme PstI. The lower panel shows the restriction fragments obtained in a control subject and in proband T.L., in whom
the c.289 C>T substitution abolishes a PstI restriction site at the 5¢ end of exon 4. The sizes of the restriction fragments are
indicated below the diagram. The upper panel shows the separation of the restriction fragments by 2% agarose gel electropho-
resis. Lanes 1 and 7: molecular weight makers; lane 2: control subject; lanes 3–5: mother, father and brother of the proband;
lane 6: proband T.L.; lane 8: undigested PCR fragment of exon 4.
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secreted by the hepatocytes would be entrapped by
heparan-sulphate proteglycans and endocytotic
receptors present at the cell surface [27]. In this way
apo A-V would facilitate lipoprotein uptake (i.e.
chylomicron remnants removal). These results are in
line with the observation that the clearance of chylo-
micron remnants is reduced in apoa5 knock-out mice
[28]. In this context one might assume that in
patients with apo A-V deficiency the LPL- mediated
TG hydrolysis of chylomicrons and VLDL is less
efficient and the clearance of lipoprotein remnants by
the liver is delayed. The magnitude of the accumula-
tion in plasma of TG- rich lipoproteins in these
patients is probably related to the amount of these
lipoproteins entering the plasma compartment. Exces-
sive secretion of chylomicrons due to a high fat
intake, or excessive secretion of VLDL by the liver
induced by various metabolic stimuli, may overload
the less efficient LPL-mediated hydrolysis of TG-rich
lipoproteins and impair the capacity of the liver
to capture lipoprotein remnants, in case of apo
A-V deficiency. This may explain why in our two
patients with apo A-V deficiency (Q97X and
Q148X) dietary interventions, aimed at reducing chy-
lomicron formation (reduced oral fat load) and ⁄or
VLDL synthesis and secretion (administration of x-3
fatty acids) [29], have such a profound TG-lowering
effect.
The other remarkable finding in proband T.L. is the
persistently low level of plasma HDL-C, which was
only marginally affected by dietary treatment. The
hypothesis that the absence of apo A-V, which is a
minor protein component of HDL, renders HDL more
unstable and more easily removed from the circula-
tion, is unlikely in view of the minute amounts of apo
A-V present in human plasma. It is more likely that
the delayed TG hydrolysis, due apo A-V deficiency
per se or due to the increased level of apo C-III (an
inhibitor of LPL) [30], reduces the availability of sur-
face components of TG-rich lipoproteins, which con-
tribute to HDL formation. It was recently shown that
adenovirus mediated delivery of apoA-V into HTG
APOC3 transgenic mice not only reduced triglyceride
and VLDL-C level but also increased HDL-C level
with an increase of both the number and size of HDL
particles [31]. These data suggest that in addition to
its TG-lowering effects, apoA-V plays a significant
role in modulating HDL maturation and cholesterol
metabolism.
The three heterozygotes for Q97X mutation investi-
gated in this study (Table 2) have normal plasma TG,
suggesting that partial apo A-V deficiency is not suffi-
cient per se to induce HTG and other predisposing
factors are required. We previously reported that only
five out of ten carriers of Q148X mutation had
moderate elevation of plasma TG (>2 mmol L)1; the
Fig. 3 Immunoblot analysis of plasma apo A-V. Plasma
proteins were separated on 10% SDS-PAGE and transferred
to PVDF membranes. Apo A-V was detected using rabbit
polyclonal antibodies directed against apo A-V and appro-
priate secondary antibody. Signals were visualized by chem-
iluminesence. Five microlitre of plasma was applied to each
lane. Lane 1: proaband T.L.; lane 2: proband’s father; lane
3: control subject. Molecular weight markers are shown on
the left.
C. Priore Oliva et al. | Case Report: Dyslipidaemia in apo A-V deficiency
456 ª 2008 Blackwell Publishing Ltd Journal of Internal Medicine 263; 450–458
highest level observed was 4.65 mmol L)1). Carriers
with elevated plasma TG tended to be older, to have
higher body mass index and higher fasting plasma
glucose level than normotriglyceridaemic carriers
[18]. Amongst the carriers of Q139X belonging to
one of the families reported by Marcais et al. [19],
two had severe HTG and four had plasma TG levels
of 2 mmol L)1 or less. The two individuals with
severe HTG had diabetes and low LPL activity.
In conclusion, we report the third mutation in APOA5
gene that results in apo A-V deficiency in a patient
with primary HTG. We also confirmed that strict die-
tary treatment and supplementation with x-3 fatty
acids induce a substantial reduction of plasma TG
level.
We predict that the systematic analysis of the major
candidate genes controlling the lipolytic cascade in
patients with primary HTG will lead to the discovery
of other loss of function mutations of APOA5 gene.
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